Curebase has announced an ongoing collaboration with Portamedic for supporting decentralised clinical trials with mobile phlebotomy services.
Under the partnership, Portamedic will be responsible for collecting tests and blood samples from the homes of participating decentralised clinical trial (DCT) individuals in the US.
At present, Curebase and Portamedic are working with Persephone Biosciences on a long-term clinical study of colorectal cancer patients.
In the DCT process, stool and blood specimens will be collected from 350 volunteers with colorectal cancer as well as 1,000 healthy people who take part the trial and categorised as either low risk or high risk for the disease.
Portamedic president and chief operating officer Jim Fritz said: “The mobile phlebotomy services Portamedic provides makes it easier for people to participate in clinical trials because they don’t have to travel to a site or some other central location to get their blood drawn.
“We’ve already been working with Curebase on clinical trials and we look forward to partnering with them on upcoming studies.”
The clinical trial, which started early this year, is part of the longitudinal, observational study, ARGONAUT, of 4,000 advanced-stage cancer patients and healthy individuals with varying cancer risk.
Precision microbiome medicines can be developed using the collected data which will further help in identifying clinically actionable cancer-specific biomarkers to guide therapeutic decisions.
Portamedic and Curebase will continue to collaborate on upcoming DCTs for expanding the number of potential participants and enabling diversity.
The DCT clinical trial model of Curebase ensures more diverse studies.
Through Curebase platform, CROs, physicians from practices and sponsors will be able to carry out clinical research.
Last month, Curebase raised $40m in a Series B financing round led by Industry Ventures to advance the development of its end-to-end clinical trial execution model.